Hiding in Plain Sight – Identify APOL1-Mediated Kidney Disease^†

Identify APOL1 variants associated with APOL1-mediated kidney disease (AMKD) with Renasight™ sponsored renal genetic testing for eligible* patients of African ancestry^††

Black Americans are 4 times more likely to develop kidney failure compared to other populations, raising the possibility of an underlying genetic contribution to this disparity^1,2

Genetic testing is a critical first step—genetic testing is the only way to confirm if a patient has AMKD.

Vertex Pharmaceuticals is sponsoring a no-cost Renasight™ renal genetic testing for eligible* patients of African ancestry diagnosed with chronic kidney disease^††

Get Started

Review the Steps Below to Get Started

Confirm patient eligibility. Review the Sponsored Renasight™ Genetic Testing Program Eligibility to confirm individuals meet criteria and get the patient’s consent to move forward with testing.
Order the test using Renasight™ requisition form and attestation form. Please note all orders must include the attestation form. Download forms here
Based on preference, collect blood or buccal specimen using the collection tube that is provided in the Renasight™ kit. If you need a kit, please contact your local sales representative or click the “get started” button below
Return the kit using the label provided at no charge
Results are available for review in about 3 weeks

Get Started

Additional Services

Complementary Genetic Counseling

Natera’s Renal Genetic Counselors (RGC’s) are trained and certified to provide genetic counseling, education, and support to clinicians, patients, and/or families who have been, or plan to be, tested with Renasight™. Our RGC’s work to provide the highest level of support to you as well as your patients and families.

Genetic CounselingSchedule Session Now

Learn more about the sponsored Renasight™ genetic testing program

Select your user type to proceed!

I am a

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company *

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

^† APOL1-mediated kidney disease as well as other genetic kidney disease diagnoses can only be made by a healthcare provider when taking into consideration all patient health information, including genetic testing results

^†† The Sponsored Renasight™ Genetic Testing Program is funded by Vertex Pharmaceuticals Incorporated. Additional terms and conditions apply. This program is subject to change or discontinuation without notice.

^{Eligible patients and healthcare providers have no expectations or obligations to Natera or Vertex Pharmaceuticals to participate in the sponsored Renasight™ Genetic Testing Program.}

^{All tests must be ordered by a qualified healthcare provider based on clinical necessity for the patient. Healthcare providers must also confirm patient eligibility criteria for the sponsored Renasight™ Genetic Testing Program and complete a signed attestation form for each patient.}

^{Natera never distributes identifiable patient data or information. Natera will never share identifiable patient data or information. Vertex Pharmaceuticals and third parties may receive aggregated, de-identified data, and contact information for healthcare providers that participate in this sponsored Renasight™ genetic testing program.}

References

¹Umeukeje EM, Young BA. Genetics and ESKD Disparities in African Americans. Am J Kidney Dis. 2019 Dec;74(6):811-821. doi: 10.1053/j.ajkd.2019.06.006. Epub 2019 Oct 10. PMID: 31606237; PMCID: PMC7373097.

²https://www.niddk.nih.gov/health-information/kidney-disease/race-ethnicity

³Elliott MD et al. J Am Soc Nephrol. 2023;34(5):909-919

Hiding in Plain Sight – Identify APOL1-Mediated Kidney Disease†

Identify APOL1 variants associated with APOL1-mediated kidney disease (AMKD) with Renasight™ sponsored renal genetic testing for eligible* patients of African ancestry††